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ABSTRACT
Patients with gastric cancer which in ltrates distal esophagus often complain of dysphagia. Stenting is 
currently the therapy of choice for malignant dysphagia. Self expanding metallic stent (SEMS) placement has 
become the standard stenting therapy.
We reported a case of 63 year old male patient with an advanced gastric adenocarcinoma which in ltrated 
distal esophagus who complained of dysphagia. The diagnosis was made based on esophago gastro duodenoscopy 
(EGD), histopathology study and contrast enhanced abdominal computed tomography (CT) scan. Patient 
underwent esophageal stenting successfully. This case report demonstrates SEMS placement as an effective 
palliation therapy in patient with an advanced gastric cancer which in ltrated distal esophagus.
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 ABSTRAK
Pasien kanker lambung yang meluas ke esofagus distal seringkali mengeluh sulit menelan. Saat ini prosedur 
stenting merupakan terapi pilihan untuk disfagia yang disebabkan adanya keganasan saluran cerna. Self 
expanding metallic stent (SEMS) merupakan terapi stenting standar.
Dilaporkan pasien laki-laki 63 tahun dengan adenokarsinoma lambung stadium lanjut yang meluas ke 
esofagus distal. Pasien mengeluh sulit menelan. Diagnosis ditegakkan berdasarkan esofago gastro duodenoscopy 
(EGD), pemeriksaan histopatologi dan CT-scan abdomen dengan kontras. Pasien berhasil menjalani prosedur 
stenting esofagus. Laporan kasus ini memperlihatkan penggunaan SEMS sebagai terapi paliatif yang efektif 
pada pasien kanker lambung stadium lanjut yang meluas ke esofagus distal.
Kata kunci: kanker lambung, self expanding metallic stent, disfagia maligna 
INTRODUCTION
One of the most prevalent malignancies in the world 
is gastric cancer. Worldwide, gastric cancer is the fourth 
most common cancer after lung, breast, and colorectal 
cancer.1,2 Gastric cancer, as any other cancer, affects 
patient’s physical and emotional conditions. Physical 
problems are dysphagia, epigastric pain, weight loss, 
bloody vomit, melena, nausea, vomiting, indigestion, 
anorexia, and post prandial fullness.1-4 From the 
emotional aspect, patient is often depressed because 
of the complicated diagnostic and treatment problems 
and also the fear of death. Overall, the whole problems 
described above can impair the patient’s quality of life. 
The treatment for gastric cancer has evolved. Early 
gastric cancer can be cured by invasive methods and 
surgery. For advanced gastric cancer, the therapy is 
mainly palliative.1-4 Stenting is currently the therapy 
of choice for the palliation of malignant dysphagia 
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caused by gastric cancer which extends to esophagus. 
Self expanding metallic stent (SEMS) placement has 
become the standard therapy which provides quick 
relief of dysphagia and further improves quality of life. 
CASE ILLUSTRATION 
A 63 year old male patient came to Cipto 
Mangunkusumo Hospital complained of dif culty in 
swallowing that has worsened since one week prior 
to admission. Since 4 months before admission, he 
often complained of epigastric pain. He was given 
medications in rural general hospital but had no 
improvement. Since 2 months before admission, 
he complained of dif culty in swallowing, nausea, 
vomiting, and decrease in appetite. He denied any 
bloody vomit. Sometimes he defecated black tarry 
stools. Epigastric pain persisted. Since 1 month before 
admission, he felt the passage of either solid or liquid 
food in upper digestive tract was obstructed. Since one 
week before admission, the dif culty of swallowing 
had worsened. Body weight decreased from 70 to 56 
kg in 4 months. He was admitted to private hospital 
but there was no improvement. He denied any history 
of previous cancer or history of cancer in the family. 
He worked as a construction labour worker. He had a 
history of smoking 1 pack of cigarette per day for 40 
years and seldom ate food with preservatives.
From the physical examination, patient looked 
moderately ill and fully alert. The vital signs were 
normal. Body weight at admission was 54 kg, and 
height was 170 cm. Body mass index was 18.7 kg/
m2. Performance status was Eastern Cooperative 
Oncology Group (ECOG) 1. Eye, ear, nose, throat, 
mouth, neck, lungs, cardiac, abdominal and extremities 
examination revealed no abnormalities except there 
was an enlargement of left supraclavicular lymph node 
with size 2 x 2 cm, hard consistency,  xed and no signs 
of in ammation.
The laboratory result on admission was hemoglobin 
(Hb) 9.7 g/dL, hematocrite (Ht) 30.7%, mean 
corpuscular volume (MCV) 83 fL, mean corpuscular 
hemoglobin (MCH) 29 pg, mean corpuscular 
hemoglobin concentration (MCHC) 31 g/dL, leukocyte 
9,650/uL, thrombocyte 556,000/uL. Liver and 
kidney function was normal. A gastric cardia mass 
which in ltrated distal esophagus was found in EGD 
examination (Figure 1). After the mass biopsy was 
done, a nasogastric tube (NGT) was also placed per 
endoscopic to provide nutrition intake for the patient 
(Figure 2).
Figure 1.  A gastric cardia mass which in ltrated distal esophagus
Figure 2. Per-endoscopic naso gastric tube placement
Pathology examination revealed intestinal type 
gastric adenocarcinoma and Helicobacter pylori 
(H. pylori) positive. The contrast enhanced abdominal 
CT scan revealed a mass in gastric cardia which 
infiltrated distal esophagus and perigastric fat, 
enlargement of paraaortic lymph node and multiple 
nodules in liver. Contrast enhanced thorax CT scan 
did not show any abnormalities.
He was diagnosed advanced gastric cancer which 
extended to distal esophagus and metastasized to the 
liver. Thus, the therapy of this patient was mainly 
palliative. 
For the dysphagia relief, he underwent SEMS 
placement (Figure 3). Right after the placement of 
SEMS, dysphagia score from 3 increased to 0. He 
could eat liquid and solid diet normally without NGT. 
He refused chemotherapy and decided to go home.
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Figure 3. Placement of self expanding metallic stent in distal 
esophagus
Patient was advised to visit gastroenterology 
clinic of Cipto Mangunkusumo Hospital within one 
week after he was discharged home. On the first 
visit, he still felt chest discomfort but denied any 
bloody vomit, melena, or dif culty in breathing. He 
could still eat normally. He did not come regularly 
to gastroenterology clinic. Four months after the 
procedure, he was reported passed away at home.
DISCUSSION
Gastric cancer is still one of the most common 
malignancies. Data from American Cancer Society 
shows that in 2007, there were one million new cases.1,2
The incidence of gastric cancer was higher in Asian and 
South American countries than in the United States. 
This malignancy occurs mostly in elderly. Male have 
twice the risk of gastric cancer than female.1,2 Risk 
factors for gastric cancer are consumption of food 
with preservatives, H. pylori infections, and genetic 
predisposition. 
This patient was diagnosed advanced stage gastric 
cancer. The overall data of the patient  tted with the 
theory described above. The patient was 63 years old, 
male, and Asian. Pathologic examination of the gastric 
tissue revealed the presence of H. pylori. These factors 
may contributed to the development of the gastric 
cancer in this patient
For palliative therapy, there are many options for 
gastric cancer that in ltrated distal esophagus. Those 
are laser ablation, photodynamic therapy and stenting. 
Dysphagia caused by malignant obstruction has the 
bene ts from SEMS placement. The goal is to minimize 
the symptoms and promote oral intake of food, water 
and medications, seal  stulas or anastomotic leaks 
following surgical interventions, minimize hospital 
stay, and ultimately to improve quality of life.5-13 This 
method also has low complication rate and potential 
long term relief.6
This patient underwent an EGD soon after the 
admission. Based on thorough examination in the ward 
and 7th American Joint Committee on Cancer Staging 
System, this patient’s problem was an advanced gastric 
cancer that had metastasized to the liver.14-16 Patient 
mainly had swallowing dif culty. Based on clinical 
manifestations, this patient was a candidate for SEMS 
placement. 
Before SEMS placement, every physician must 
perform pre-procedure evaluation. This includes 
evaluation of indications, contra-indications and the 
preparation of the stent. The common indications for 
the placement of SEMS are palliation of malignant 
dysphagia in patients with tumors of the esophagus 
and gastric cardia, extra esophageal tumors (such 
as lung cancer and malignant lymphadenopathy), 
tracheoesophageal  stulas (in advanced esophageal 
and lung cancer), esophageal perforation (usually 
iatrogenic from direct endoscopic trauma or following 
stricture dilatation), anastomotic tumor recurrence 
following surgery, and benign esophageal strictures 
refractory to balloon dilatation and not suitable for 
surgery.12,13,16-19
The indication of SEMS placement for this patient 
was malignant dysphagia caused by an advanced 
gastric cancer which in ltrated distal esophagus. It 
was inoperable. 
Currently, there are no absolute contra indications 
for SEMS placement. There are some relative contra 
indications, such as platelet count less than 50,000/
mm3 and international normalized ratio (INR) over than 
1.5, recent high dose of chemotherapy or radiotherapy 
(3-6 weeks) because of increased hemorrhage and 
perforation rates, severely ill patients, obstructive 
lesion of stomach due to peritoneal seeding, severe 
tracheal compression that would be worsened by 
esophageal stenting, and extremely high stenosis close 
to vocal cords.12,16,17
There were no contraindications of SEMS placement 
in this patient. INR and platelet count were within 
normal limits. The patient also had not undergone any 
chemotherapy or radiotherapy. Patient was not severely 
ill. There was no peritoneal seeding clinically and 
radiologically. Patient did not have any complain of 
breathlessness. Based on pre-procedure evaluation, the 
patient was a perfect candidate for SEMS placement.
The choice of stent depends on many factors, such as 
tumor length and position, presence of  stula, potential 
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airway compromise, and personal preference of the 
individual inserting the stent. The diameter and length 
of the stent should be determined after measuring the 
length of the obstruction using endoscopy. The length 
of the stent chosen should be at least 3 to 4 cm longer 
than the obstruction to allow an adequate margin of 
stent on the side of obstruction.17 Placement of metallic 
stent for tumor in gastric cardia and distal esophagus 
is associated with speci c problems because the distal 
part of the stent projects freely into the fundus of the 
stomach and cannot  x itself to the wall. Uncovered 
stents are preferred for tumors in the cardia because 
they are less likely to migrate. Covered stents are 
advocated for tumors with high risk of  stula formation 
or when a  stula already exists. These are also used 
to avoid ingrowth of tumor through the metal mesh. 
A metallic stent placed across the gastroesophageal 
junction leads to gastroesophageal re ux in patients.17
The chosen metallic stent in this patient was the 
uncovered type to minimize the migration risk of the 
stent. Metallic stent length was 15 cm with the diameter 
of 2 cm. 
After the stent placement, physicians need to 
evaluate the dysphagia score, any other symptoms, and 
complications related to procedure. Dysphagia score 
should improve. Patients will occasionally feel chest 
pain, which can be controlled by analgesics and opiates. 
It is important to make sure whether the chest pain is 
related to acid re ux or not. Additional precautions 
should be taken, such as elevating the head of the bed 
and avoiding recumbence within 3 hours after the meal.17 
Complications caused by metallic stent placement are 
immediate, early, and late complications. Immediate 
(at the time of placement) complications encompass 
aspiration, airway compromise, malposition, delivery 
system entrapment, stent dislodgement, incomplete 
deployment and perforation. Early (up to 1 week 
after stent placement) complications include bleeding, 
chest pain, and nausea. Late complications (beyond 1 
week of successful stent placement) include recurrent 
dysphagia due to obstruction from tumor or food 
impaction, migration, tracheoesophageal fistula, 
bleeding, and gastroesophageal re ux disease.20-23 
The dysphagia score before SEMS placement was 
3 (dysphagia to solid and liquids). After the SEMS 
placement, the dysphagia score was 0. Patient felt 
relieved and could eat and drink normally. This patient 
was instructed to elevate his head in the bed and was 
prescribed intravenous analgetics. Patient was also 
prescribed proton pump inhibitor to suppress acid 
secretion. 
At the time of deployment, patient did not have 
any complications. There were no aspirations, 
breathlessness, malposition, delivery system 
entrapment, stent dislodgement, incomplete deployment 
nor perforation. Within 1 week, patient complained 
a chest pain which was relieved by analgetics. To 
evaluate bleeding, we asked the patient whether there 
was any bloody vomit or melena. He denied any bloody 
vomit and melena. We also evaluated serial complete 
blood count to evaluate if there was any decrease 
in hemoglobin. From the result of complete blood 
count, we did not  nd any decrease in hemoglobin 
and hematocrite. Patient also did not feel any nausea. 
Late complications are also the one that we should 
seek. After 1 week, when the patient visited the 
gastroenterology clinic, he did not complain dif culty 
in swallowing or bleeding. However, he complained 
of slight chest pain which was relieved by analgetics. 
Patient did not complain any sour taste in his mouth. 
Overall, the SEMS placement was successful for the 
palliation of his malignant dysphagia. 
Management of advanced gastric cancer is mainly 
palliative. The options of palliative therapy are widely 
available. One of the effective palliative therapies for 
dysphagia symptoms are placement of SEMS. SEMS 
placement requires thorough examination which 
encompasses pre-procedure assessment, deployment, 
and post-procedure observation. 
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